The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of bevacizumab in combination with irinotecan plus S-1 as first-line treatment in patients with KRAS mutant-type metastatic colorectal cancer.
 
Tetsuya Eto
Honoraria - Chugai Pharma; Taiho Pharmaceutical; Takeda
 
Toshiki Masuishi
Honoraria - Chugai Pharma; Taiho Pharmaceutical; Takeda
 
Kohei Suzuki
No Relationships to Disclose
 
Isamu Shibata
No Relationships to Disclose
 
Yuichi Fukami
No Relationships to Disclose
 
Toru Matsui
No Relationships to Disclose
 
Takashi Ichida
No Relationships to Disclose
 
Fumihiko Kusano
No Relationships to Disclose
 
Junichi Tazawa
No Relationships to Disclose
 
Yoshinori Sakai
No Relationships to Disclose